Sorrento Therapeutics Releases Positive Results from Asthma Trial

Sorrento Therapeutics has released positive data from a combination Phase 2/Phase 3 clinical study in China evaluating its STI-004 biosimilar of Genentech’s Xolair in patients suffering from allergic asthma.

The candidate reached its primary endpoint of reducing asthma exacerbations, with 21 percent of patients taking STI-004 experiencing asthma exacerbation versus 55 percent in the placebo group.